Arbutus Biopharma Corp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 169,695 | -33,501 | -29,745 | -22,003 | -24,526 |
| Depreciation Amortization | 11 | 363 | 352 | 341 | 330 |
| Accounts receivable | 1,160 | 1,375 | 1,504 | 1,384 | 1,227 |
| Other Working Capital | -178,866 | -10,023 | -11,821 | -12,971 | 5,269 |
| Other Operating Activity | -110 | 2,149 | 4,753 | 4,109 | 4,309 |
| Operating Cash Flow | $-8,110 | $-39,637 | $-34,957 | $-29,140 | $-13,391 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 2,200 | 15,216 | 16,932 | 26,951 | 11,349 |
| PPE Investments | N/A | 364 | 9 | 9 | N/A |
| Other Investing Activity | -1 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | $2,199 | $15,580 | $16,941 | $26,960 | $11,349 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 11,619 | 5,721 | 4,081 | 3,237 | 2,784 |
| Financing Cash Flow | $11,619 | $5,721 | $4,081 | $3,237 | $2,784 |
| Exchange Rate Effect | -10 | 14 | 13 | 25 | 4 |
| Beginning Cash Position | 18,008 | 36,330 | 36,330 | 36,330 | 36,330 |
| End Cash Position | 23,706 | 18,008 | 22,408 | 37,412 | 37,076 |
| Net Cash Flow | $5,698 | $-18,322 | $-13,922 | $1,082 | $746 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,110 | -39,637 | -34,957 | -29,140 | -13,391 |
| Free Cash Flow | -8,110 | -39,637 | -34,957 | -29,140 | -13,391 |